Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
about
Emerging therapies for acute myeloid leukemia.Is there a standard induction regimen for patients with AML?Recent advances in the treatment of acute myeloid leukemia.Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience.Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Comparison of carbon-sulfur and carbon-amine bond in therapeutic drug: 4β-S-aromatic heterocyclic podophyllum derivatives display antitumor activity.Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposideTherapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signalingClinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.The evolving landscape in the therapy of acute myeloid leukemia.Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide.The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia.Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults.Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.Chemotherapy protocols and incidence of oral mucositis. An integrative review.Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectivesDissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
P2860
Q33576363-352B559C-9EB5-4482-A270-EBC935DA95D0Q33952411-8944A6B8-A901-48D6-BEE6-845A0586AEEBQ34082437-9F45FB6D-3F17-42ED-BC4B-58988B3DAF53Q34543008-7668C639-5237-4062-8653-2E577417C65DQ35667279-F485DFF9-1CD0-4386-96B3-DE4C9DD4E682Q35859437-67A3E885-3870-4F15-B4D9-7E5B21AD2449Q36129142-734A6014-7B85-4259-991B-49442575FAD6Q36727867-7CFFE763-38E6-4123-B629-175AFDFE4E96Q37201853-B11019EF-9B20-4C99-A1DF-F2145DC16D04Q37271941-6E6305FA-ABCD-485E-8D1B-34338B58BF16Q37289691-1E6C91F0-93EA-4FF0-AB74-2EB89F2FDE30Q37323006-849BF16F-F555-4EEC-B012-28FF1F9827ADQ37411669-561A1021-AF72-4057-A6DC-E3E420FFAA3EQ37586897-2CE5E40A-8FAB-4C18-A5D7-D455647902D1Q37607838-4F7CE12E-9CD8-4975-9F1C-C6ED26F4F306Q37659087-D85E486C-481E-4060-94DF-ED9268272C3AQ38132064-2E7B66AC-8F5A-4592-8521-EA46D45CB936Q40728154-18485DCB-9167-4ADD-B018-36263A3229B3Q42943359-08275AFA-1B2A-4D37-8925-116DCD7B9B77Q46168137-64074948-1629-4AF3-AFB7-31EA385BAFC1Q49840237-D9418EFB-3C85-4B6E-8D95-91CFD68C93D0Q55024194-7AA13CEA-1A0D-4826-8E8A-1B9DA737F9F7Q55472969-7D9D853D-ACBA-48FC-9CB7-E308471723FCQ58555302-7254F800-9B5D-4B38-A4BE-48E3D0089DFCQ58718483-A4E510D8-3E96-4CDE-857D-6BA7CBF99953
P2860
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
description
1990 nî lūn-bûn
@nan
1990 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@ast
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@en
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@nl
type
label
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@ast
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@en
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@nl
prefLabel
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@ast
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@en
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group.
@nl
P2093
P1433
P1476
Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group
@en
P2093
Cobcroft R
Kronenberg H
Lowenthal RM
Matthews JP
Whiteside MG
P407
P577
1990-01-01T00:00:00Z